ATE525477T1 - Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren - Google Patents
Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basierenInfo
- Publication number
- ATE525477T1 ATE525477T1 AT99916365T AT99916365T ATE525477T1 AT E525477 T1 ATE525477 T1 AT E525477T1 AT 99916365 T AT99916365 T AT 99916365T AT 99916365 T AT99916365 T AT 99916365T AT E525477 T1 ATE525477 T1 AT E525477T1
- Authority
- AT
- Austria
- Prior art keywords
- cxcr
- role
- gene expression
- tumorgenesis
- therapeutic
- Prior art date
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 title abstract 5
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 101150033839 4 gene Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7991698P | 1998-03-30 | 1998-03-30 | |
US10465698P | 1998-10-16 | 1998-10-16 | |
PCT/US1999/007431 WO1999050461A1 (en) | 1998-03-30 | 1999-03-29 | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE525477T1 true ATE525477T1 (de) | 2011-10-15 |
Family
ID=26762563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99916365T ATE525477T1 (de) | 1998-03-30 | 1999-03-29 | Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren |
Country Status (12)
Country | Link |
---|---|
US (3) | US20050202019A1 (de) |
EP (2) | EP2308996A1 (de) |
JP (3) | JP4786793B2 (de) |
AT (1) | ATE525477T1 (de) |
AU (2) | AU766675B2 (de) |
CA (2) | CA2731416A1 (de) |
DE (1) | DE1068357T1 (de) |
DK (1) | DK1068357T3 (de) |
ES (1) | ES2156581T5 (de) |
GR (1) | GR20010300028T1 (de) |
NZ (2) | NZ528767A (de) |
WO (1) | WO1999050461A1 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6863887B1 (en) | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
EP2308996A1 (de) * | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutische und diagnostische Anwendungen auf Grundlage der Wirkung der CXCR-4 und SDF-1 Gene in der Tumorigenese |
EP1050583A4 (de) * | 1998-11-24 | 2005-02-02 | Hisamitsu Pharmaceutical Co | Inhibitoren einer hiv-infektion. |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
LT2371361T (lt) * | 2001-07-31 | 2019-09-10 | Genzyme Corporation | Pirmtakų/kamieninių ląstelių suaktyvinimo būdai |
EP1438400B1 (de) | 2001-10-01 | 2009-06-17 | Dyax Corp. | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
US20040009171A1 (en) * | 2001-10-18 | 2004-01-15 | Genentech, Inc. | Methods for the treatment of carcinoma |
US7253007B2 (en) | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
US20090291087A1 (en) * | 2002-03-21 | 2009-11-26 | University Of Florida Research Foundation, Inc. | Modulating angiogenesis |
JP2005528362A (ja) * | 2002-03-21 | 2005-09-22 | ユニヴァーシティ オヴ フロリダ | 血管新生の調節法 |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20140170116A9 (en) | 2002-08-22 | 2014-06-19 | Marc S. Penn | Method of treating ischemic disorders |
US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
AU2003291549A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
WO2004055041A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
EP1606251B1 (de) | 2002-12-20 | 2009-04-08 | ChemoCentryx Inc | Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor |
JP4963701B2 (ja) | 2005-04-21 | 2012-06-27 | ケモセントリックス インコーポレーティッド | Ccx−ckr2を結合する試薬 |
US20090054322A1 (en) * | 2005-05-26 | 2009-02-26 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
US20070123448A1 (en) * | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
JP2009525055A (ja) * | 2006-02-01 | 2009-07-09 | ザ バーナム インスティテュート フォー メディカル リサーチ | 腫瘍および前癌性病変におけるリンパ管のジップコード |
ES2396220T3 (es) * | 2006-08-11 | 2013-02-20 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1) |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP3753947A1 (de) | 2007-09-14 | 2020-12-23 | Adimab, LLC | Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon |
WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
WO2009079451A2 (en) | 2007-12-14 | 2009-06-25 | The Cleveland Clinic Foundation | Compositions and methods of promoting wound healing |
GB0802754D0 (en) * | 2008-02-14 | 2008-03-26 | Inst Superiore Di Sanito | Antisense RNA targetting CXCR4 |
US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
CN102099378B (zh) | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
CN103396473A (zh) | 2008-11-04 | 2013-11-20 | 安科治疗公司 | Cxcr4受体化合物 |
US20120283315A1 (en) | 2009-08-28 | 2012-11-08 | Penn Marc S | Sdf-1 delivery for treating ischemic tissue |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
EP2566494B1 (de) | 2010-02-26 | 2017-11-29 | Acer Therapeutics, Inc. | Cxcr4-rezeptorverbindungen |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
CN103282560B (zh) | 2010-07-16 | 2016-08-03 | 阿迪马布有限责任公司 | 抗体文库 |
CN103108641B (zh) * | 2010-09-09 | 2016-01-13 | 诺松制药股份公司 | Sdf-1结合性核酸及其在癌症治疗中的用途 |
US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
BR112013029482A2 (pt) | 2011-05-16 | 2016-08-09 | Genzyme Corp | utilização de antagonistas cxr4 |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
AR087364A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
CN115261411A (zh) | 2013-04-04 | 2022-11-01 | 哈佛学院校长同事会 | 利用CRISPR/Cas***的基因组编辑的治疗性用途 |
EP3019595A4 (de) | 2013-07-09 | 2016-11-30 | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen | |
HUP1300509A2 (hu) * | 2013-08-30 | 2015-03-30 | Gabor Firneisz | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
US10968426B2 (en) | 2015-05-08 | 2021-04-06 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
EP3389720A1 (de) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetalpolymere, konjugate, partikel und verwendungen davon |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
WO2018191476A1 (en) | 2017-04-12 | 2018-10-18 | Magenta Therapeutics, Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
CN111542597A (zh) | 2017-10-31 | 2020-08-14 | 美真达治疗公司 | 用于扩增造血干细胞和祖细胞的组合物和方法 |
AU2018358054A1 (en) | 2017-10-31 | 2020-05-07 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
CN111712262A (zh) | 2017-12-06 | 2020-09-25 | 美真达治疗公司 | 用于动员造血干细胞和祖细胞的给药方案 |
JP2021510150A (ja) | 2018-01-03 | 2021-04-15 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 造血幹細胞および前駆細胞の増幅ならびに遺伝性代謝障害の処置のための組成物および方法 |
US20220401481A1 (en) | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
AU2021263754A1 (en) | 2020-04-27 | 2022-12-01 | Ensoma, Inc. | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
CA1289880C (en) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
DE69032483T2 (de) | 1989-10-05 | 1998-11-26 | Optein, Inc., Seattle, Wash. | Zellfreie synthese und isolierung von genen und polypeptiden |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
WO1992006180A1 (en) | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
US5543503A (en) * | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
JP4156662B2 (ja) | 1991-03-29 | 2008-09-24 | ジェネンテック・インコーポレーテッド | ヒトpf4a受容体とその使用 |
US5840856A (en) * | 1991-03-29 | 1998-11-24 | Genentech, Inc. | Antibodies to a human PF4 superfamily receptor |
US5776457A (en) * | 1991-03-29 | 1998-07-07 | Genentech, Inc. | Antibodies to human PF4A receptor and compositions thereof |
DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
ES2149774T3 (es) | 1991-06-05 | 2000-11-16 | Univ Connecticut | Aportacion dirigida de genes que codifican proteinas secretoras. |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
EP0633943A4 (de) | 1992-04-03 | 1997-05-02 | Alexander T Young | Gentherapy unter verwendung zielgerichteter viraler vektoren. |
PT671923E (pt) | 1992-10-09 | 2001-10-30 | Advanced Tissue Sciences Inc | Celulas de reserva do figado |
UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
JP3367581B2 (ja) * | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞 |
EP0854918A1 (de) * | 1996-01-30 | 1998-07-29 | The National Institutes of Health | Zellen, die sowohl menschliches cd4 als auch cxcr4 exprimieren |
WO1997049424A1 (en) * | 1996-06-25 | 1997-12-31 | The Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
FR2751658B1 (fr) * | 1996-07-26 | 1998-10-02 | Pasteur Institut | Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih |
US5939538A (en) * | 1996-10-25 | 1999-08-17 | Immusol Incorporated | Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
US6946445B1 (en) * | 1998-03-13 | 2005-09-20 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
EP2311495B1 (de) | 1998-03-24 | 2014-09-24 | Chugai Seiyaku Kabushiki Kaisha | Inhibitoren der Vaskularisierung |
EP2308996A1 (de) * | 1998-03-30 | 2011-04-13 | NorthWest Biotherapeutics, Inc. | Therapeutische und diagnostische Anwendungen auf Grundlage der Wirkung der CXCR-4 und SDF-1 Gene in der Tumorigenese |
WO1999065507A1 (en) * | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
1999
- 1999-03-29 EP EP10184637A patent/EP2308996A1/de not_active Withdrawn
- 1999-03-29 CA CA2731416A patent/CA2731416A1/en not_active Abandoned
- 1999-03-29 ES ES99916365.2T patent/ES2156581T5/es not_active Expired - Lifetime
- 1999-03-29 JP JP2000541348A patent/JP4786793B2/ja not_active Expired - Fee Related
- 1999-03-29 DE DE1068357T patent/DE1068357T1/de active Pending
- 1999-03-29 WO PCT/US1999/007431 patent/WO1999050461A1/en active IP Right Grant
- 1999-03-29 NZ NZ528767A patent/NZ528767A/en unknown
- 1999-03-29 NZ NZ507161A patent/NZ507161A/en unknown
- 1999-03-29 AU AU34702/99A patent/AU766675B2/en not_active Ceased
- 1999-03-29 AT AT99916365T patent/ATE525477T1/de active
- 1999-03-29 CA CA2323525A patent/CA2323525C/en not_active Expired - Fee Related
- 1999-03-29 EP EP99916365.2A patent/EP1068357B2/de not_active Expired - Lifetime
- 1999-03-29 DK DK99916365.2T patent/DK1068357T3/da active
-
2001
- 2001-06-29 GR GR20010300028T patent/GR20010300028T1/el unknown
-
2004
- 2004-02-12 AU AU2004200560A patent/AU2004200560B2/en not_active Ceased
- 2004-11-09 US US10/985,324 patent/US20050202019A1/en not_active Abandoned
-
2009
- 2009-02-06 US US12/367,308 patent/US8409566B2/en not_active Expired - Fee Related
-
2010
- 2010-10-01 JP JP2010224077A patent/JP2011021030A/ja not_active Withdrawn
-
2013
- 2013-04-02 US US13/855,626 patent/US9566294B2/en not_active Expired - Fee Related
- 2013-11-25 JP JP2013243021A patent/JP5992897B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP5992897B2 (ja) | 2016-09-14 |
US8409566B2 (en) | 2013-04-02 |
JP2011021030A (ja) | 2011-02-03 |
AU766675B2 (en) | 2003-10-23 |
US20050202019A1 (en) | 2005-09-15 |
AU2004200560A1 (en) | 2004-03-11 |
EP1068357B2 (de) | 2014-12-10 |
US20140072564A1 (en) | 2014-03-13 |
NZ507161A (en) | 2003-12-19 |
JP2014043460A (ja) | 2014-03-13 |
GR20010300028T1 (en) | 2001-06-29 |
US9566294B2 (en) | 2017-02-14 |
CA2731416A1 (en) | 1999-10-07 |
CA2323525C (en) | 2011-03-01 |
JP2002509734A (ja) | 2002-04-02 |
DE1068357T1 (de) | 2001-07-19 |
ES2156581T5 (es) | 2015-01-21 |
EP1068357B1 (de) | 2011-09-21 |
DK1068357T3 (da) | 2011-12-12 |
WO1999050461A9 (en) | 2000-02-17 |
CA2323525A1 (en) | 1999-10-07 |
EP2308996A1 (de) | 2011-04-13 |
EP1068357A1 (de) | 2001-01-17 |
ES2156581T3 (es) | 2012-02-03 |
WO1999050461A1 (en) | 1999-10-07 |
JP4786793B2 (ja) | 2011-10-05 |
US20100062003A1 (en) | 2010-03-11 |
AU2004200560B2 (en) | 2007-09-20 |
AU3470299A (en) | 1999-10-18 |
ES2156581T1 (es) | 2001-07-01 |
NZ528767A (en) | 2005-08-26 |
EP1068357A4 (de) | 2003-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE525477T1 (de) | Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
IL143748A0 (en) | Substituted aryl or heteroarylamides having retinoid-like biological activity | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
HU9301314D0 (en) | Quinazoline derivatves for improving anto-tumouric activity | |
TW263423B (de) | ||
IL100810A0 (en) | Tetrahydropyrimidine derivatives and pharmaceutical compositions comprising them | |
PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
DE60003025D1 (en) | Arylsulfonyle als faktor xa inhibitoren | |
DE69308999D1 (de) | Strukturaufklärung und Synthese von Phenethylamiden des Antineoplastischen Tetrapeptides Dolastatin 10 | |
ATE355278T1 (de) | Isochinolinon derivate als parp inhibitoren | |
ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
MX9700557A (es) | Dihidrobenzofuranos. | |
DE69716925D1 (de) | Isoxazoline derivate und ihre verwendung als antimikroben | |
DE69334243D1 (de) | Synthetische polynukleotide | |
ATE342911T1 (de) | Synthese von nukleosiden und polynukleotiden | |
DE69824433D1 (en) | Proteintyrosinphosphatase inhibitoren | |
UA72948C2 (uk) | Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів | |
TR199801871A2 (xx) | Bifenilsulfonilsiyanamidler �retim y�ntemi ve ila� olarak kullan�mlar�. | |
ZA961364B (en) | 1-Aryl-2-acylamino-ethane compounds | |
DE69937301D1 (de) | Aminosterolderivate und ihre verwendungen | |
DE60013994D1 (de) | 1,2-Disubstituierte 1,4-Dihydro-4-oxochinolin-Verbindungen | |
NO20003397D0 (no) | 3 '-empiriske K-252A-derivater | |
HK1008225A1 (en) | Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone | |
ITRM920305A0 (it) | Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1068357 Country of ref document: EP |